title: MR imaging monitoring of iron-labeled pancreatic islets in a small series of patients: islet fate in successful, unsuccessful, and autotransplantation.
abstract: Islet transplantation is one of the most promising and effective therapies for restoring normoglycemia in type 1 diabetes (T1D) patients, but islet engraftment is one of the main obstacles hampering long-term success. Monitoring graft loss, caused either by immunological or nonimmunological events, occurring in the first phase after transplantation and at later stages of a patient's life is a very important issue. Among the imaging approaches previously applied, magnetic resonance imaging (MRI) monitoring of islet fate following labeling with superparamagnetic iron oxide agents yielded promising results. The aim of this study was to translate into patients the method of islet labeling and MRI monitoring developed in our preclinical setting and to compare imaging results with graft clinical outcome.Three T1D patients and one nondiabetic patient undergoing autotransplantation following subtotal pancreatectomy received Endorem(®)-labeled islets. Patients were monitored by MRI and metabolically (HbA1c, exogenous insulin requirement, and C-peptide, TEF) at 1, 3, and 7 days following transplantation and once a month up to 10 months. Labeled transplanted islets appeared as hypointense areas scattered within the liver parenchyma, whose absolute number at 24 h after transplantation reflected the labeling efficiency. In patients #1 and #3 with good midterm graft function, MRI follow-up showed an important early loss of hypointense spots followed by a slow and progressive disappearance at later timepoints. Graft loss of function in patient #2 4 weeks after transplantation was associated with the complete disappearance of all hypointense signals. The autotransplanted patient, stably insulin free, showed no significant signal reduction during the first 3 days, followed by loss of spots similar to a patient with good midterm graft function. These results suggest that MRI monitoring of islet transplantation at early time points could represent a meaningful readout for helping in predicting transplant failure or success, but its relevance for mid/long-term islet function assessment appears evanescent.
authors.affiliation: Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Malosio
authors.forename: Antonio
authors.initials: A
authors.lastname: Esposito
authors.forename: Cristina
authors.initials: C
authors.lastname: Brigatti
authors.forename: Anna
authors.initials: A
authors.lastname: Palmisano
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Piemonti
authors.forename: Rita
authors.initials: R
authors.lastname: Nano
authors.forename: Paola
authors.initials: P
authors.lastname: Maffi
authors.forename: Francesco
authors.initials: F
authors.lastname: De Cobelli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Del Maschio
authors.forename: Antonio
authors.initials: A
authors.lastname: Secchi
mesh_terms: D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000032:analysis*; D003911:Dextrans / Q000032:analysis*; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D005260:Female; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014182:Transplantation, Autologous
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; C065507:ferumoxides